FOR IMMEDIATE RELEASE Contact: Neal G. Koller
President & CEO
1 May 2008 Board of Directors
443 994 0101
PLUROGEN THERAPEUTICS INC. AND WELCARE INDUSTRIES, S.p.a.
SIGN AGREEMENT TO COMMERCIALIZE
COMMERCIALIZE NEW PRODUCT UTILIZING PLUROGEN TECHNOLOGY
(Charlottesville, VA, May 1, 2008) – Following on to the Letter of Intent signed in December, 2007, PluroGen
Therapeutics, Inc. today announced an agreement with Welcare Industries S.p.a. (Orvieto, Italy) to develop and
commercialize new wound and skin cleansing products based on PluroGen’s proprietary core topical gel
technology.
Commenting on the Agreement, Neal G. Koller, President & CEO of PluroGen, said, “Signing the definitive
agreement with Welcare further progresses our plans for fast market entry for our core technology. This is a
strategic and an important relationship to provide PluroGen with solid footing in Europe and entry into a new
market. Welcare is an established European leader in wound and skin cleansing products and technology. This
relationship will add to PluroGen’s product offerings and facilitate entry into the European market.”
Fulvia Lazzarotto, Managing Director for Welcare, stated, “PluroGen technology and products will provide Welcare
with new, differentiated and superior products in skin and wound cleansing. We look forward to their launch and
success. Our relationship with Plurogen is important for our future product offerings.”
About PluroGen Therapeutics, Inc.
PluroGen is a wound healing company commercializing its four patent-protected technology platforms. The
Company’s core gel technology provides superior and differentiated physical and bio-active benefits to wound
healing. The technology is configurable to deliver drug and non-drug compounds as protected and advanced
therapeutic products for simple and complex wound healing. PluroGen’s product pipeline targets improved,
protected therapies for the 6 Areas of Therapeutic Treatment of tissue healing (cleansing, infection, pain,
inflammation, tissue salvage, tissue regeneration).
PluroGen’s first gel, PluroGel™, is being used initially as a component in skin and wound cleansing products, as
topical barrier product, and, for two branded topical antimicrobial products, PluroGel™ Silver Sulfadiazine and
PluroGel™ TAG. PluroGel™ TAG is currently in routine use at the University of Virginia Medical Center, having
shown superior results on more than 2,000 patients in two different patient populations, severe burns and
chronic wounds. The PluroGen management and operational teams, Boards and Principal Investigators are
recognized global clinical and commercial leaders in PluroGen’s target markets of burn and wound care and in the
life sciences industry.
For more information about PluroGen Therapeutics, Inc., visit the Company’s web site at www.plurogen.com.
About the Welcare Industries, S.p.a.
Welcare Industries, S.p.a. is a privately held European medical device company with manufacturing, distribution
and headquarters in Orvieto, Italy. Welcare was founded in 1997 and focuses on wound and total patient
cleansing products, clinical and patient protection products and specialty procedure products. Welcare is
currently selling its products in major European countries.
For more information about Welcare Industries, S.p.a., visit the Company’s web site at www.welcaremedical.com.
Statements included in this press release that are not historical in nature are "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995. The Company cautions readers that forward-looking
statements are subject to certain risks and uncertainties, which could cause actual results to differ materially and
which are identified from time to time in the Company’s reports filed with the U.S. Securities and Exchange
Commission. PluroGen Therapeutics, Inc. claims the protection of the Safe Harbor for forward-looking statements
contained in the Private Securities Litigation Reform Act of 1995.
Information included on PluroGen Therapeutics, Inc website or Welcare Industries, S.p.a website is not incorporated herein by
reference or otherwise.
President & CEO
1 May 2008 Board of Directors
443 994 0101
PLUROGEN THERAPEUTICS INC. AND WELCARE INDUSTRIES, S.p.a.
SIGN AGREEMENT TO COMMERCIALIZE
COMMERCIALIZE NEW PRODUCT UTILIZING PLUROGEN TECHNOLOGY
(Charlottesville, VA, May 1, 2008) – Following on to the Letter of Intent signed in December, 2007, PluroGen
Therapeutics, Inc. today announced an agreement with Welcare Industries S.p.a. (Orvieto, Italy) to develop and
commercialize new wound and skin cleansing products based on PluroGen’s proprietary core topical gel
technology.
Commenting on the Agreement, Neal G. Koller, President & CEO of PluroGen, said, “Signing the definitive
agreement with Welcare further progresses our plans for fast market entry for our core technology. This is a
strategic and an important relationship to provide PluroGen with solid footing in Europe and entry into a new
market. Welcare is an established European leader in wound and skin cleansing products and technology. This
relationship will add to PluroGen’s product offerings and facilitate entry into the European market.”
Fulvia Lazzarotto, Managing Director for Welcare, stated, “PluroGen technology and products will provide Welcare
with new, differentiated and superior products in skin and wound cleansing. We look forward to their launch and
success. Our relationship with Plurogen is important for our future product offerings.”
About PluroGen Therapeutics, Inc.
PluroGen is a wound healing company commercializing its four patent-protected technology platforms. The
Company’s core gel technology provides superior and differentiated physical and bio-active benefits to wound
healing. The technology is configurable to deliver drug and non-drug compounds as protected and advanced
therapeutic products for simple and complex wound healing. PluroGen’s product pipeline targets improved,
protected therapies for the 6 Areas of Therapeutic Treatment of tissue healing (cleansing, infection, pain,
inflammation, tissue salvage, tissue regeneration).
PluroGen’s first gel, PluroGel™, is being used initially as a component in skin and wound cleansing products, as
topical barrier product, and, for two branded topical antimicrobial products, PluroGel™ Silver Sulfadiazine and
PluroGel™ TAG. PluroGel™ TAG is currently in routine use at the University of Virginia Medical Center, having
shown superior results on more than 2,000 patients in two different patient populations, severe burns and
chronic wounds. The PluroGen management and operational teams, Boards and Principal Investigators are
recognized global clinical and commercial leaders in PluroGen’s target markets of burn and wound care and in the
life sciences industry.
For more information about PluroGen Therapeutics, Inc., visit the Company’s web site at www.plurogen.com.
About the Welcare Industries, S.p.a.
Welcare Industries, S.p.a. is a privately held European medical device company with manufacturing, distribution
and headquarters in Orvieto, Italy. Welcare was founded in 1997 and focuses on wound and total patient
cleansing products, clinical and patient protection products and specialty procedure products. Welcare is
currently selling its products in major European countries.
For more information about Welcare Industries, S.p.a., visit the Company’s web site at www.welcaremedical.com.
Statements included in this press release that are not historical in nature are "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995. The Company cautions readers that forward-looking
statements are subject to certain risks and uncertainties, which could cause actual results to differ materially and
which are identified from time to time in the Company’s reports filed with the U.S. Securities and Exchange
Commission. PluroGen Therapeutics, Inc. claims the protection of the Safe Harbor for forward-looking statements
contained in the Private Securities Litigation Reform Act of 1995.
Information included on PluroGen Therapeutics, Inc website or Welcare Industries, S.p.a website is not incorporated herein by
reference or otherwise.
PluroGen Therapeutics, Inc.
503 Broadleaf Way
Charlottesville, VA 22911
Tel: 443 994 0101
Fax: 410 990 9817
www.plurogen.com
503 Broadleaf Way
Charlottesville, VA 22911
Tel: 443 994 0101
Fax: 410 990 9817
www.plurogen.com
| News Release |
